In today’s briefing:
- IndiQube Spaces Ltd Pre-IPO Tearsheet
- Pre-IPO Jiangsu Hengrui Medicine – High Valuation Cannot Be Justified
IndiQube Spaces Ltd Pre-IPO Tearsheet
- IndiQube Spaces Ltd (1628202D IN) (ISL) is looking to raise about US$100m in its upcoming India IPO. The bookrunners for the deal are ICICI and JM fin.
- IndiQube Spaces Limited (ISL) is a managed workplace solutions provider offering technological workplace solutions.
- According to CBRE Report, ISL is among the leading operators in Bengaluru as of Jun 24.
Pre-IPO Jiangsu Hengrui Medicine – High Valuation Cannot Be Justified
- Hengrui plans to IPO in Hong Kong, but it hasn’t yet completed the business transformation from generic drugs to innovative drugs, and is still facing the negative impact of VBP.
- The key point is whether the innovative drug business has sustained high enough growth rate to offset the decline in generic drug business so as to support the high valuation.
- Hengrui is overvalued in A-Share. We think Hengrui’s valuation should be lower than that of BeiGene (6160 HK) and Hansoh Pharmaceutical Group (3692 HK) in Hong Kong stock market.
Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
Unlock all research summaries